|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001128,
umls-concept:C0004015,
umls-concept:C0020792,
umls-concept:C0052350,
umls-concept:C0205314,
umls-concept:C0243076,
umls-concept:C0330390,
umls-concept:C0559956,
umls-concept:C0679622,
umls-concept:C0920591,
umls-concept:C2003941,
umls-concept:C2699006
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2001-12-12
|
|
pubmed:abstractText |
Potent non-peptidic alpha(v)beta(3) antagonists have been prepared incorporating various beta-amino acids as aspartic acid mimetics. Modification of the beta-alanine 3-substituents alters the potency and physicochemical properties of these receptor antagonists and in some cases provides orally bioavailable alpha(v)beta(3) inhibitors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:AskewBen CBC,
pubmed-author:BrashearKaren MKM,
pubmed-author:BreslinMichael JMJ,
pubmed-author:ColemanPaul JPJ,
pubmed-author:DugganMark EME,
pubmed-author:Fernandez-MetzlerCarmenC,
pubmed-author:HartmanGeorge DGD,
pubmed-author:HoffmanWilliam FWF,
pubmed-author:HuntCecilia ACA,
pubmed-author:HutchinsonJohn HJH,
pubmed-author:LeuChih TaiCT,
pubmed-author:LibbyLaura ALA,
pubmed-author:LynchJoseph JJJ,
pubmed-author:LynchRobertR,
pubmed-author:MaBennettB,
pubmed-author:McVeanCarol ACA,
pubmed-author:MerkleKara MKM,
pubmed-author:PrueksaritanontThomayantT,
pubmed-author:RodanGideon AGA,
pubmed-author:RodanSevgi BSB,
pubmed-author:StumpGary LGL,
pubmed-author:WallaceAudrey AAA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
7
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
31-4
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11738567-Amino Acids,
pubmed-meshheading:11738567-Animals,
pubmed-meshheading:11738567-Aspartic Acid,
pubmed-meshheading:11738567-Binding, Competitive,
pubmed-meshheading:11738567-Dogs,
pubmed-meshheading:11738567-Drug Evaluation, Preclinical,
pubmed-meshheading:11738567-Humans,
pubmed-meshheading:11738567-Inhibitory Concentration 50,
pubmed-meshheading:11738567-Molecular Mimicry,
pubmed-meshheading:11738567-Oligopeptides,
pubmed-meshheading:11738567-Osteoporosis,
pubmed-meshheading:11738567-Protein Binding,
pubmed-meshheading:11738567-Receptors, Vitronectin,
pubmed-meshheading:11738567-Structure-Activity Relationship
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. paul_coleman@merck.com
|
|
pubmed:publicationType |
Journal Article
|
